Nasopharyngeal carcinoma · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Gemcitabine (GC) Variant #34 | — | R 15 338 | 56d | ~7.4 mo | ~27.9 mo | ~5 | ~R 76 690 PFS proxy · indirect | 8 |
Capecitabine monotherapy Variant #17 | — | R 2 219 | 21d | ~35.9 mo | ~15.3 mo | ~53 | ~R 117 626 PFS proxy · indirect | 2 |
Cisplatin and Fluorouracil (CF) Variant #29 | — | R 1 900 | 21d | ~20.1 mo | ~18.6 mo | ~30 | ~R 57 002 PFS proxy · indirect | 3 |
Carboplatin and Fluorouracil Variant #01 | — | R 1 781 | 21d | — | ~7.4 mo | — | — | 1 |
Observation Partial | — | — | — | — | — | — | — | 1 |
5 of 5 regimens shown